Analysts Set Expectations for TNGX FY2026 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for Tango Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.58) per share for the year. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $12.20.

Tango Therapeutics Stock Up 6.0%

Shares of TNGX opened at $4.74 on Wednesday. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $12.02. The company has a market capitalization of $513.79 million, a PE ratio of -4.02 and a beta of 1.24. The stock has a fifty day simple moving average of $1.88 and a two-hundred day simple moving average of $2.40.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $6.73 million.

Institutional Trading of Tango Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. TCG Crossover Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $33,174,000. Boxer Capital Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $32,077,000. Gilead Sciences Inc. purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $15,000,000. Farallon Capital Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $12,360,000. Finally, Nantahala Capital Management LLC purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $8,666,000. 78.99% of the stock is owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.